

## **NET Device Corp Announces Start of Multi-Centre NeuroElectric Therapy (NET™) Study in Scotland**

MT. LAUREL, New Jersey – March 25, 2009 – NET Device Corp, a leading developer of medical devices for the treatment of drug addiction, today announced that recruitment has commenced in a major clinical trial involving the Company's CE-marked NET Model 804 medical device. The study will compare the impact of NeuroElectric Therapy (NET™) against standard recovery methods, on acute and chronic drug withdrawal outcomes at multiple residential rehabilitation centres across Scotland.

NET uses non-invasive transcranial electrostimulation to treat persons addicted to alcohol, cocaine, heroin, methadone, methamphetamines and other drugs and drug combinations. NET Device Corp's medical devices deliver NET waveforms, tailored to the drug abuse profile of the addicted individual, to detoxify and substantially remove long term cravings. Previous studies have shown that combining NET with residential rehabilitation produces drug-free behaviour in 80% of subjects at 1 to 8 years from treatment.

The study will assess whether NET combined with standard treatment within a residential rehabilitation setting is more effective in ameliorating symptoms of drug withdrawal and facilitating addict abstinence from prescribed and non-prescribed drugs in the short, medium and long term, than standard treatment alone within this setting. Recruitment of a total of 140 subjects with significant and long-term drug dependency problems will come from multiple Scottish rehabilitation centres, with 70 subjects randomly assigned to receive NET treatment and 70 to the control non-NET treatment group. In addition to examining the impact of NET on detoxification, craving reduction, long-term abstinence, and the economics of drug rehabilitation, NET's mechanism of action will be investigated by pioneering brain imaging.

This ground-breaking study is being undertaken in conjunction with researchers at the University of Glasgow's Centre for Drug Misuse Research, the Faculty of Medicine at Imperial College London, the Centre for Health Economics at the University of York, and the National Health Service. BlueVector Limited in Edinburgh is overseeing regulatory compliance of the study.

"The start of this comprehensive clinical trial of NET marks an important step in establishing its place in the spectrum of treatments on offer to addicts wishing to tackle their drug dependencies", commented Joe Winston, CEO of NET Device Corp.

### **About NET Device Corp**

NET Device Corp is the world's leading innovator and provider of transcranial electrical stimulators for drug addiction. The Company develops,

manufactures, and markets innovative, science-based NET medical devices that greatly ameliorate the undesirable acute symptoms of detoxification and substantially remove the long term cravings of individuals addicted to licit and illicit substances. Privately held NET Device Corp is headquartered in Mt. Laurel, NJ, USA, with subsidiaries in the UK and South Africa.

For further information, please go to NET Device Corp's website at [www.netdevice.net](http://www.netdevice.net).

**Contact:**

Joe Winston, CEO  
NET Device Corp  
[jwinston@netdevice.net](mailto:jwinston@netdevice.net)